Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cell Reports|August 15, 2019
Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor GrowthSarbajeet Nagdas, Jennifer A Kashatus, Aldo Nascimento, et al.
Journal of Surgical Oncology|July 17, 2024
Survival benefit associated with screening of patients at elevated risk for pancreatic cancerWilliam J Kane, Kathleen R Haden, Elizabeth N Martin, et al.
Plos One|November 9, 2013
Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimensDustin M Walters, Jayme B Stokes, Sara J Adair, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2020
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsXiaolong Wei, Jiekun Yang, Sara J Adair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2017
CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic CancerAlex D Michaels, Timothy E Newhook, Sara J Adair, et al.
Molecular Cancer Therapeutics|September 10, 2011
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironmentJayme B Stokes, Sara J Adair, Jill K Slack-Davis, et al.
Neoplasia (New York, N.Y.)|February 27, 2013
Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinibDustin M Walters, James M Lindberg, Sara J Adair, et al.
Nature Communications|October 17, 2018
CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug responseKarol Szlachta, Cem Kuscu, Turan Tufan, et al.
Cancer Research|March 12, 2024
A Histone Methylation-MAPK Signaling Axis Drives Durable Epithelial-Mesenchymal Transition in Hypoxic Pancreatic CancerBrooke A Brown, Paul J Myers, Sara J Adair, et al.
Developmental Cell|May 4, 2022
ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancerHarun Ozturk, Harun Cingoz, Turan Tufan, et al.
Pageof 4